PKC theta inhibitor (EpiAxis Therapeutics/Icahn School of Medicine)

N/A

Report date: 2025/03/20 09:23:10
NME

Base Information

Drug NamePKC theta inhibitor (EpiAxis Therapeutics/Icahn School of Medicine)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProtein kinase C theta inhibitors
TargetsProtein kinase C theta
Therapy Area/IndicationsTriple Negative Breast NeoplasmsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesEpiaxis Therapeutics Pty Ltd
China Registration ClassN/A

Develop Information

Active CompaniesEpiaxis Therapeutics Pty LtdIcahn School Of Medicine At Mount Sinai
Inactive CompaniesN/A
Active IndicationsTriple Negative Breast Neoplasms
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A